Monthly Archives: May 2013

Valuable Alternative To Animal Models Predicts Reactions To Novel Drugs And Cosmetics

A simple lab-based skin test which eliminates the risk of adverse reactions to new drugs, cosmetics and household chemicals has been developed by a Newcastle University, UK team. It uses real human skin and immune cells to show any reaction such as a rash or blistering indicating a wider immune response within the body...

Study Evaluates Prevalence Of Multiple Health Concerns Among Patients With The Alopecia Areata

JAMA Dermatology Study Highlights A study by Kathie P. Huang, M.D., of Brigham and Women's Hospital, Boston, and colleagues examined the prevalence of comorbid (co-existing) conditions among patients with alopecia areata (AA), an autoimmune disease that presents with nonscarring hair loss from some or all hair-bearing areas of the body, typically the scalp...

Study Suggests Cutaneous Squamous Cell Carcinoma Carries Risk Of Metastasis And Death

JAMA Dermatology Study Highlights A study by Chrysalyne D. Schmults, M.D., M.S.C.E., of Brigham and Women's Hospital, Boston, and colleagues suggests cutaneous squamous cell carcinoma (CSCC) carries a low but significant risk of metastasis and death. The ten-year retrospective cohort study was conducted at an academic medical center in Boston, and included 985 patients with 1,832 tumors...

Research Letter Suggests Twitter May Serve As A Good Forum For Communicating Information About Acne

JAMA Dermatology Study Highlights A research letter by Kamal Jethwani, M.D., M.P.H., of the Center for Connected Health, Boston, and colleagues suggests that clinicians can learn about the perceptions and misconceptions of diseases like acne via Twitter, and communicate reliable medical information on the popular social media platform...

Creabilis Announces Headline Results Of Its Phase 2b Trial Of Topical TrkA Kinase Inhibitor CT327

Clinically and Statistically Significant Reduction of Chronic Pruritus (Itch) Seen in Psoriasis Patients Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), has announced headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients...